207 related articles for article (PubMed ID: 36626330)
1. Inhibition of Nicotine Metabolism by Cannabidiol (CBD) and 7-Hydroxycannabidiol (7-OH-CBD).
Nasrin S; Coates S; Bardhi K; Watson C; Muscat JE; Lazarus P
Chem Res Toxicol; 2023 Feb; 36(2):177-187. PubMed ID: 36626330
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Predictions of Cytochrome P450 (P450)-Mediated In Vivo Cannabinoid-Drug Interactions Based on Reversible and Time-Dependent P450 Inhibition in Human Liver Microsomes.
Bansal S; Paine MF; Unadkat JD
Drug Metab Dispos; 2022 Apr; 50(4):351-360. PubMed ID: 35115300
[TBL] [Abstract][Full Text] [Related]
3. CYP2C19 Plays a Major Role in the Hepatic
Perez-Paramo YX; Watson CJW; Chen G; Lazarus P
Drug Metab Dispos; 2023 Jan; 51(1):29-37. PubMed ID: 35197312
[TBL] [Abstract][Full Text] [Related]
4. Cannabidiol and cannabidiolic acid: Preliminary in vitro evaluation of metabolism and drug-drug interactions involving canine cytochrome P-450, UDP-glucuronosyltransferase, and P-glycoprotein.
Court MH; Mealey KL; Burke NS; Jimenez TP; Zhu Z; Wakshlag JJ
J Vet Pharmacol Ther; 2024 Jan; 47(1):1-13. PubMed ID: 37469115
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of UDP-Glucuronosyltransferase Enzymes by Major Cannabinoids and Their Metabolites.
Nasrin S; Watson CJW; Bardhi K; Fort G; Chen G; Lazarus P
Drug Metab Dispos; 2021 Dec; 49(12):1081-1089. PubMed ID: 34493601
[TBL] [Abstract][Full Text] [Related]
6. Impact of Genetic Variants in the Nicotine Metabolism Pathway on Nicotine Metabolite Levels in Smokers.
Perez-Paramo YX; Watson CJW; Chen G; Thomas CE; Adams-Haduch J; Wang R; Khor CC; Koh WP; Nelson HH; Yuan JM; Lazarus P
Cancer Epidemiol Biomarkers Prev; 2023 Jan; 32(1):54-65. PubMed ID: 36252563
[TBL] [Abstract][Full Text] [Related]
7. Cannabinoid Metabolites as Inhibitors of Major Hepatic CYP450 Enzymes, with Implications for Cannabis-Drug Interactions.
Nasrin S; Watson CJW; Perez-Paramo YX; Lazarus P
Drug Metab Dispos; 2021 Dec; 49(12):1070-1080. PubMed ID: 34493602
[TBL] [Abstract][Full Text] [Related]
8. Role of human cytochrome P4502A6 in C-oxidation of nicotine.
Nakajima M; Yamamoto T; Nunoya K; Yokoi T; Nagashima K; Inoue K; Funae Y; Shimada N; Kamataki T; Kuroiwa Y
Drug Metab Dispos; 1996 Nov; 24(11):1212-7. PubMed ID: 8937855
[TBL] [Abstract][Full Text] [Related]
9. Variation in trans-3'-hydroxycotinine glucuronidation does not alter the nicotine metabolite ratio or nicotine intake.
Zhu AZ; Zhou Q; Cox LS; Ahluwalia JS; Benowitz NL; Tyndale RF
PLoS One; 2013; 8(8):e70938. PubMed ID: 23936477
[TBL] [Abstract][Full Text] [Related]
10. Interindividual variability in nicotine metabolism: C-oxidation and glucuronidation.
Nakajima M; Yokoi T
Drug Metab Pharmacokinet; 2005 Aug; 20(4):227-35. PubMed ID: 16141602
[TBL] [Abstract][Full Text] [Related]
11. Cytochrome P450-Catalyzed Metabolism of Cannabidiol to the Active Metabolite 7-Hydroxy-Cannabidiol.
Beers JL; Fu D; Jackson KD
Drug Metab Dispos; 2021 Oct; 49(10):882-891. PubMed ID: 34330718
[TBL] [Abstract][Full Text] [Related]
12. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity.
Dempsey D; Tutka P; Jacob P; Allen F; Schoedel K; Tyndale RF; Benowitz NL
Clin Pharmacol Ther; 2004 Jul; 76(1):64-72. PubMed ID: 15229465
[TBL] [Abstract][Full Text] [Related]
13. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes.
Messina ES; Tyndale RF; Sellers EM
J Pharmacol Exp Ther; 1997 Sep; 282(3):1608-14. PubMed ID: 9316878
[TBL] [Abstract][Full Text] [Related]
14. Genetic determinants of cytochrome P450 2A6 activity and biomarkers of tobacco smoke exposure in relation to risk of lung cancer development in the Shanghai cohort study.
Yuan JM; Nelson HH; Butler LM; Carmella SG; Wang R; Kuriger-Laber JK; Adams-Haduch J; Hecht SS; Gao YT; Murphy SE
Int J Cancer; 2016 May; 138(9):2161-71. PubMed ID: 26662855
[TBL] [Abstract][Full Text] [Related]
15. Nicotine 5'-oxidation and methyl oxidation by P450 2A enzymes.
Murphy SE; Raulinaitis V; Brown KM
Drug Metab Dispos; 2005 Aug; 33(8):1166-73. PubMed ID: 15860657
[TBL] [Abstract][Full Text] [Related]
16. Characterization of CYP2A6 involved in 3'-hydroxylation of cotinine in human liver microsomes.
Nakajima M; Yamamoto T; Nunoya K; Yokoi T; Nagashima K; Inoue K; Funae Y; Shimada N; Kamataki T; Kuroiwa Y
J Pharmacol Exp Ther; 1996 May; 277(2):1010-5. PubMed ID: 8627511
[TBL] [Abstract][Full Text] [Related]
17. Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes.
Jiang R; Yamaori S; Takeda S; Yamamoto I; Watanabe K
Life Sci; 2011 Aug; 89(5-6):165-70. PubMed ID: 21704641
[TBL] [Abstract][Full Text] [Related]
18. Glucuronidation of trans-3'-hydroxycotinine by UGT2B17 and UGT2B10.
Chen G; Giambrone NE; Lazarus P
Pharmacogenet Genomics; 2012 Mar; 22(3):183-90. PubMed ID: 22228205
[TBL] [Abstract][Full Text] [Related]
19. CYP2A6 AND CYP2B6 are involved in nornicotine formation from nicotine in humans: interindividual differences in these contributions.
Yamanaka H; Nakajima M; Fukami T; Sakai H; Nakamura A; Katoh M; Takamiya M; Aoki Y; Yokoi T
Drug Metab Dispos; 2005 Dec; 33(12):1811-8. PubMed ID: 16135656
[TBL] [Abstract][Full Text] [Related]
20. Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6.
Yamaori S; Okamoto Y; Yamamoto I; Watanabe K
Drug Metab Dispos; 2011 Nov; 39(11):2049-56. PubMed ID: 21821735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
